Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Hydroxychloroquine, Telmisartan, Azithromycin and Curcumin on Survival in Elderly Hospitalized COVID-19 Patients
2020-001303-16Phase 3Terminated
- Sponsor
- Strasbourg University Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine, telmisartan, azithromycin and curcumin in coronavirus disease 2019 (COVID-19) and bacterial disease (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Two-week survival rate. Started Mar 2020; status: terminated.
02
Drugs
hydroxychloroquinetelmisartanazithromycincurcumin
03
Conditions
coronavirus disease 2019 (COVID-19)bacterial disease
Beyond the preview
Go deeper on 2020-001303-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001303-16.